Skin microvascular dysfunction as an early cardiovascular marker in primary hyperoxaluria type I.


Journal

Pediatric nephrology (Berlin, Germany)
ISSN: 1432-198X
Titre abrégé: Pediatr Nephrol
Pays: Germany
ID NLM: 8708728

Informations de publication

Date de publication:
02 2019
Historique:
received: 17 04 2018
accepted: 03 09 2018
revised: 03 08 2018
pubmed: 3 10 2018
medline: 3 4 2020
entrez: 3 10 2018
Statut: ppublish

Résumé

Primary hyperoxaluria type 1 (PH1) is an orphan inborn error of oxalate metabolism leading to hyperoxaluria, progressive renal failure, oxalate deposition, and increased cardiovascular complications. As endothelial dysfunction and arterial stiffness are early markers of cardiovascular risk, we investigated early endothelial and vascular dysfunction in young PH1 patients either under conservative treatment (PH1-Cons) or after combined kidney liver transplantation (PH1-T) in comparison to healthy controls (Cont-H) and patients with a past of renal transplantation (Cont-T). Skin microvascular function was non-invasively assessed by laser Doppler flowmetry before and after stimulation by current, thermal, or pharmacological (nitroprussiate (SNP) or acetylcholine (Ach)) stimuli in young PH1 patients and controls. Seven PH1-Cons (6 F, median age 18.2) and 6 PH1-T (2 F, median age 13.3) were compared to 96 Cont-H (51 F, median age 14.2) and 6 Cont-T (4 F, median age 14.5). The endothelium-independent vasodilatation (SNP) was severely decreased in PH1-T compared to Cont-H. Ach, current-induced vasodilatation (CIV), and thermal response was increased in PH1-Cons and Cont-T compared to controls. PH1-T patients displayed severely decreased smooth muscle capacity to vasodilate. An exacerbated endothelial-dependent vasodilation suggests a role for silent inflammation in the early dysfunction of microcirculation observed in PH1-Cons and Cont-T.

Sections du résumé

BACKGROUND
Primary hyperoxaluria type 1 (PH1) is an orphan inborn error of oxalate metabolism leading to hyperoxaluria, progressive renal failure, oxalate deposition, and increased cardiovascular complications. As endothelial dysfunction and arterial stiffness are early markers of cardiovascular risk, we investigated early endothelial and vascular dysfunction in young PH1 patients either under conservative treatment (PH1-Cons) or after combined kidney liver transplantation (PH1-T) in comparison to healthy controls (Cont-H) and patients with a past of renal transplantation (Cont-T).
METHODS
Skin microvascular function was non-invasively assessed by laser Doppler flowmetry before and after stimulation by current, thermal, or pharmacological (nitroprussiate (SNP) or acetylcholine (Ach)) stimuli in young PH1 patients and controls.
RESULTS
Seven PH1-Cons (6 F, median age 18.2) and 6 PH1-T (2 F, median age 13.3) were compared to 96 Cont-H (51 F, median age 14.2) and 6 Cont-T (4 F, median age 14.5). The endothelium-independent vasodilatation (SNP) was severely decreased in PH1-T compared to Cont-H. Ach, current-induced vasodilatation (CIV), and thermal response was increased in PH1-Cons and Cont-T compared to controls.
CONCLUSIONS
PH1-T patients displayed severely decreased smooth muscle capacity to vasodilate. An exacerbated endothelial-dependent vasodilation suggests a role for silent inflammation in the early dysfunction of microcirculation observed in PH1-Cons and Cont-T.

Identifiants

pubmed: 30276532
doi: 10.1007/s00467-018-4081-5
pii: 10.1007/s00467-018-4081-5
doi:

Types de publication

Controlled Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

319-327

Références

Circulation. 1999 May 11;99(18):2434-9
pubmed: 10318666
Circulation. 2002 Aug 6;106(6):640-2
pubmed: 12163419
Microvasc Res. 2004 Mar;67(2):203-6
pubmed: 15020212
Diabetes. 2004 Mar;53(3):721-5
pubmed: 14988257
Hematol Oncol Stem Cell Ther. 2018 Jun;11(2):118-121
pubmed: 29066173
Eur J Clin Pharmacol. 2003 Jun;59(2):99-102
pubmed: 12721772
Circulation. 2008 Aug 26;118(9):968-76
pubmed: 18725503
Circ J. 2010 Jan;74(1):24-33
pubmed: 19920359
Int J Nephrol. 2011;2011:864580
pubmed: 21748001
Clin J Am Soc Nephrol. 2012 Mar;7(3):458-65
pubmed: 22223608
Pediatr Nephrol. 2016 Sep;31(9):1517-29
pubmed: 27060059
Vasc Med. 2009 May;14(2):137-42
pubmed: 19366820
Hypertension. 2001 Sep;38(3):434-8
pubmed: 11566918
Clin J Am Soc Nephrol. 2016 Nov 7;11(11):1962-1968
pubmed: 27630183
Clin J Am Soc Nephrol. 2014 Mar;9(3):468-77
pubmed: 24385516
J Hypertens. 2005 Jan;23(1):7-17
pubmed: 15643116
Am J Hypertens. 2015 Dec;28(12):1480-8
pubmed: 25944878
Retina. 2016 Nov;36(11):2227-2235
pubmed: 27135212
Circulation. 2007 Jul 3;116(1):85-97
pubmed: 17606856
Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):337-42
pubmed: 18855646
Kidney Int. 2009 Oct;76(7):767-73
pubmed: 19571789
Nephrol Dial Transplant. 2012 May;27(5):1729-36
pubmed: 22547750
Expert Opin Investig Drugs. 2013 Jan;22(1):117-29
pubmed: 23167815
Am J Physiol Renal Physiol. 2008 Jan;294(1):F1-9
pubmed: 17928410
J Physiol. 2003 Sep 1;551(Pt 2):705-11
pubmed: 12824443
Nat Rev Nephrol. 2012 Jun 12;8(8):467-75
pubmed: 22688746
Pediatr Nephrol. 2018 Dec;33(12):2227-2237
pubmed: 29322327
Pediatr Nephrol. 2013 Dec;28(12):2273-81
pubmed: 23494551
Kidney Int. 2004 Aug;66(2):746-52
pubmed: 15253729
J Am Coll Cardiol. 2003 Oct 1;42(7):1149-60
pubmed: 14522472
J Atheroscler Thromb. 2012;19(3):276-84
pubmed: 22146236
Kidney Int. 2007 Aug;72(3):247-59
pubmed: 17568785
Trends Pharmacol Sci. 2013 Jul;34(7):373-84
pubmed: 23791036
PLoS One. 2012;7(4):e36056
pubmed: 22563439
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):119-26
pubmed: 26656319
J Invest Dermatol. 2010 Mar;130(3):849-55
pubmed: 19727122
Kidney Int. 2014 Dec;86(6):1197-204
pubmed: 24988064
J Am Soc Nephrol. 2018 Jun;29(6):1615-1623
pubmed: 29588429
Pediatr Transplant. 2016 Jun;20(4):523-9
pubmed: 27061278
Nephrol Dial Transplant. 2012 Oct;27(10):3855-62
pubmed: 22844106
Liver Transpl. 2014 Dec;20(12):1475-85
pubmed: 25267365
Nephrol Dial Transplant. 2018 Apr 1;33(4):552-560
pubmed: 28992218
Circulation. 2000 Nov 28;102(22):2739-44
pubmed: 11094041
Exp Ther Med. 2017 Nov;14(5):4615-4619
pubmed: 29201159

Auteurs

Alexandra Bruel (A)

Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France.
Service de Pédiatrie, Hôpital Mère et Enfants, Centre hospitalo-universitaire de Nantes, Nantes, France.

Justine Bacchetta (J)

Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.

Tiphanie Ginhoux (T)

EPICIME-CIC 1407 de Lyon, Inserm, Service de Pharmacologie Clinique, CHU-Lyon, Lyon, France.

Christelle Rodier-Bonifas (C)

Service d'ophtalmologie, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, Lyon, France.

Anne-Laure Sellier-Leclerc (AL)

Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France.

Bérengère Fromy (B)

Laboratory of Tissue Biology and Therapeutic Engineering, UMR 5305 CNRS, University Claude Bernard Lyon 1, Villeurbanne, France.

Pierre Cochat (P)

Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France.
Université Claude Bernard Lyon 1, Lyon, France.
Laboratory of Tissue Biology and Therapeutic Engineering, UMR 5305 CNRS, University Claude Bernard Lyon 1, Villeurbanne, France.

Dominique Sigaudo-Roussel (D)

Laboratory of Tissue Biology and Therapeutic Engineering, UMR 5305 CNRS, University Claude Bernard Lyon 1, Villeurbanne, France.

Laurence Dubourg (L)

Centre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hospices Civils de Lyon, Lyon, France. laurence.dubourg@chu-lyon.fr.
Université Claude Bernard Lyon 1, Lyon, France. laurence.dubourg@chu-lyon.fr.
Laboratory of Tissue Biology and Therapeutic Engineering, UMR 5305 CNRS, University Claude Bernard Lyon 1, Villeurbanne, France. laurence.dubourg@chu-lyon.fr.
Néphrologie, Dialyse, Hypertension et Exploration Fonctionnelle Rénale, Groupement Hospitalier Edouard Herriot, Hospices Civils de Lyon, Lyon, France. laurence.dubourg@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH